TAVELLA, KETTY
TAVELLA, KETTY
Evolution of Adjuvant Chemotherapy for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and Trastuzumab, Between 2000 and 2017
2019 Tommaso Susini, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori
Expression of FGD3 gene as prognostic factor in young breast cancer patients
2019 Renda, Irene; Bianchi, Simonetta; Vezzosi, Vania; Nori, Jacopo; Vanzi, Ermanno; Tavella, Ketty; Susini, Tommaso
Long Term Results after Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience
2020 Milo Giani, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori, Ermanno Vanzi, Simonetta Bianchi, Tommaso Susini
Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer
2022 Giani, Milo; Tavella, Ketty; Renda, Irene; Tartarotti, Enrico; Nori, Jacopo; Vanzi, Ermanno; Bianchi, Simonetta; Susini, Tommaso
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations
2017 Tavella, K; Villanucci, A; Vannini, L; Rossi, V; Fantechi, B; Capone, G; Putignano, A L; Gensini, F; Porfirio, B; Amunni, G; Mazzei, T; Mini, E; Papi, L
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin
2017 Tavella, K; Villanucci, A; Vannini, L; Lavacchi, D; Montelatici, S; Amunni, G; Mazzei, T
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.
2014 Susini T; Berti B; Carriero C; Tavella K; Nori J; Vanzi E; Molino C; Di Tommaso M; Santini M; Saladino V; Bianchi S
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
2018 Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Evolution of Adjuvant Chemotherapy for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and Trastuzumab, Between 2000 and 2017 | 2019 | Tommaso Susini, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori | |
| Expression of FGD3 gene as prognostic factor in young breast cancer patients | 2019 | Renda, Irene; Bianchi, Simonetta; Vezzosi, Vania; Nori, Jacopo; Vanzi, Ermanno; Tavella, Ketty; Susini, Tommaso | |
| Long Term Results after Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | 2020 | Milo Giani, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori, Ermanno Vanzi, Simonetta Bianchi, Tommaso Susini | |
| Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer | 2022 | Giani, Milo; Tavella, Ketty; Renda, Irene; Tartarotti, Enrico; Nori, Jacopo; Vanzi, Ermanno; Bianchi, Simonetta; Susini, Tommaso | |
| Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations | 2017 | Tavella, K; Villanucci, A; Vannini, L; Rossi, V; Fantechi, B; Capone, G; Putignano, A L; Gensini, F; Porfirio, B; Amunni, G; Mazzei, T; Mini, E; Papi, L | |
| Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin | 2017 | Tavella, K; Villanucci, A; Vannini, L; Lavacchi, D; Montelatici, S; Amunni, G; Mazzei, T | |
| Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. | 2014 | Susini T; Berti B; Carriero C; Tavella K; Nori J; Vanzi E; Molino C; Di Tommaso M; Santini M; Saladino V; Bianchi S | |
| Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors | 2018 | Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E |